- Home
- ALIT vs PHAT Comparison
ALIT vs PHAT Comparison
Compare ALIT & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALIT | PHAT |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 826.0M | 894.0M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ALIT | PHAT |
|---|---|---|
| Price | $0.92 | $10.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $3.75 | ★ $19.50 |
| AVG Volume (30 Days) | ★ 40.1M | 967.8K |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | ★ 17.63% | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,262,000,000.00 | $175,110,000.00 |
| Revenue This Year | N/A | $91.62 |
| Revenue Next Year | $0.14 | $59.82 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $0.65 | $2.21 |
| 52 Week High | $6.39 | $18.31 |
Technical Indicators
Market Signals| Indicator | ALIT | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 38.39 | 35.03 |
| Support Level | $0.65 | $7.82 |
| Resistance Level | $0.97 | $12.77 |
| Average True Range (ATR) | 0.07 | 0.80 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 78.62 | 7.28 |
Price Performance
Historical ComparisonAbout ALIT Alight Inc.
Alight Inc is a technology-enabled services company delivering human capital management solutions to many of complex organizations. This includes the implementation and administration of employee benefits (e.g., health, wealth and leaves benefits) solutions, currently operates under one reportable segment, Employer Solutions. The Company completed the Divestiture of Alight's Professional Services segment and Alight's Payroll & HCM Outsourcing business within the Employer Solutions segment. The company operates in USA states and International market too.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.